中国麻风皮肤病杂志 ›› 2022, Vol. 38 ›› Issue (6): 393-395.doi: 10.12144/zgmfskin202206393

• 病例报告 • 上一篇    下一篇

司库奇尤单抗治疗银屑病导致严重湿疹一例

王娜,暴芳芳,崔晓晨,周盛基,施仲香   

  1. 山东第一医科大学附属皮肤病医院（山东省皮肤病医院），山东省皮肤病性病防治研究所，济南，250022
  • 出版日期:2022-06-15 发布日期:2022-04-14
  • 通讯作者: 施仲香，E-mail：szxsd2003@sina.com

Severe eczema in one patient with secukinumab for plaque psoriasis: a case report

WANG Na, BAO Fangfang, CUI Xiaochen, ZHOU Shengji, SHI Zhongxiang   

  1. Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology, Shandong First Medical University, Jinan 250022, China
  • Online:2022-06-15 Published:2022-04-14
  • Contact: SHI Zhongxiang, E-mail: szxsd2003@sina.com

PDF (PC)

231

摘要： Secukinumab是第一个完全人源化的抗白介素17A单克隆抗体，已成功治疗中重度斑块状银屑病。这些新的靶向药物越来越普遍，但长期副作用尚不完全清楚.目前国际上已有患者应用司库奇尤单抗后出现类似汗疱疹和痤疮样皮损皮疹的报道。本文报道司库奇尤单抗治疗银屑病患者后发生严重红皮病，并出现手足汗疱疹样改变1例。

关键词: 司库奇尤单抗, 斑块状银屑病, 汗疱疹

Abstract: Secukinumab was the first fully human anti-interleukin-17a monoclonal antibody and successfully treated moderate-severe psoriasis. These new targeted medications are becoming more popular, but long-term side effects are not entirely clear. Dyshidrotic eczema and pompholyx are rare variants of dermatitis characterized by vesicles or bullae on the palms, soles and sides of the fingers. At present, the cases of patients with similar skin rashes after using secukinumab in the world have been reported. Herein, we present one case of erythroderma, accompany with dyshidrotic eczema in a patient with secukinumab for psoriasis.

Key words: secukinumab, plaque psoriasis, dyshidrotic eczema